The European Commission on Tuesday authorized the use of Eisai and Biogen's (BIIB) drug to treat mild cognitive impairment in the early stages of Alzheimer's Disease
Analysis details (16:42)
- On Monday, Biogen (BIIB) announced that final process for the EC decision on Lecanemab's marketing authorisation application is underway.
15 Apr 2025 - 16:42- Equities- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts